DALK-AD with big bubble effective

Article

Deep anterior lamellar keratoplasties by air dissection (DALK-AD) using the big bubble (BB) technique provides good visual outcomes in keratoconus treatment.

Deep anterior lamellar keratoplasties by air dissection (DALK-AD) using the big bubble (BB) technique provides good visual outcomes in keratoconus treatment, reveals a study in Cornea.

Dr David Smadja et al., National Reference Centre for Keratoconus, Bordeaux University Hospital, France, performed 44 consecutive keratoplasties on 42 keratoconus patients between January 2008 to June 2010. The team analysed the outcomes of the DALK-AD that wasn't converted to penetrating keratoplasty and a learning curve was created to achieve DALK-AD using BB.

Of the DALK-AD procedures performed, 32 were successful and 12 were converted to penetrating keratoplasty during the surgical procedure. At 12 months follow-up mean best-corrected logarithm of the minimum angle of resolution visual acuity was 0.88 ± 0.14.

Best-corrected visual acuity of ≥20/30 was seen in 93.3% of patients and 100% achieved best-corrected visual acuity of ≥20/40. At six and twelve months follow-up the mean gain of visual acuity in logarithm of the minimum angle of resolution lines was 6.12 ± 3.97 and 6.94 ± 4.18, respectively.

The DALK-AD with BB is a safe and effective technique for the surgical treatment of keratoconus. However, surgeons will need a learning period to reduce intraoperative complications.

The abstract for this investigation can be found here .

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.